| 摘要 |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: there is disclosed an application of complex iron (III) compounds with poly-maltha, hydrogenated dextrins or maltodextrin oxidation products for reparing an oral drug for iron deficiencies in patients suffering a chronic inflammatory intestinal disease, particularly Crohn's disease and nonspecific ulcerative colitis. When having been administered, the declared drugs have not invoked oxidative stress in contrast to iron sulphate therapy. ^ EFFECT: declared compounds are well tolerable, provide high compliance. ^ 8 cl, 1 dwg, 3 tbl, 1 ex |
